Tesaro, Inc.
1000 Winter Street
Suite 3300
Waltham,
MA 02451
United States - Map
Phone: 339-970-0900
Website: http://www.tesarobio.com
TESARO, Inc., an oncology-focused biopharmaceutical company, engages in the identification, acquisition, development, and commercialization of oncology therapeutics and supportive care products in the United States, Europe, and other international markets. Its product portfolio consist of the Rolapitant, a neurokinin-1 receptor antagonist, which is in Phase III clinical trials for the prevention of chemotherapy induced nausea and vomiting; Niraparib, an orally active and potent poly polymerase inhibitor that has undergone a Phase I clinical trial in cancer patients; and TSR-011, an orally available anaplastic lymphoma kinase inhibitor, which is in Phase 1/2 dose escalation clinical trials in cancer patients. The company was founded in 2010 and is headquartered in Waltham, Massachusetts. Key Statistics
| |
| | Pay | Exercised | Mr. Leon O. Moulder Jr., M.B.A.,
55
Co-Founder, Chief Exec. Officer and Director | 476.00K | 0.00 | Dr. Mary Lynne Hedley Ph.D.,
50
Co-Founder, Pres, Chief Scientific Officer and Director | 457.00K | 0.00 | Mr. Richard J. Rodgers ,
46
Co-Founder, Chief Financial Officer, Exec. VP, Treasurer and Sec. | 382.00K | 0.00 | Mr. Edward C. English ,
45
Principal Accounting Officer, VP and Controller | N/A | N/A |
|
| | Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year. | | Currency in USD. |
|
0.91%